Your session is about to expire
← Back to Search
Anti-metabolites
Combination Chemotherapy for Colorectal Cancer
Phase 1 & 2
Waitlist Available
Research Sponsored by Stony Brook University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Histologically proven recurrent or metastatic primary colorectal carcinoma with measurable disease (evaluable disease acceptable in Phase I)
Performance Status: ECOG 0-3
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is studying how well giving combination chemotherapy consisting of fluorouracil, leucovorin, and gemcitabine works in treating patients with colorectal cancer that has spread to other parts of the body.
Who is the study for?
This trial is for individuals with recurrent or metastatic colorectal cancer. They must have a certain level of platelets, acceptable liver function (even if they have liver metastases), and be able to use effective contraception if fertile. Pregnant or lactating people are excluded, as well as those who've had certain recent treatments.Check my eligibility
What is being tested?
The study is testing the effectiveness of combining three chemotherapy drugs: fluorouracil, leucovorin, and gemcitabine. The goal is to see if this mix can better kill tumor cells in patients with advanced colorectal cancer that has returned or spread.See study design
What are the potential side effects?
Chemotherapy side effects can include nausea, vomiting, hair loss, fatigue, increased risk of infection due to low blood cell counts, mouth sores and diarrhea. Specific side effects from these drugs may vary from person to person.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My colorectal cancer has returned or spread, and it can be measured.
Select...
I can care for myself but may not be able to do active work.
Select...
My liver function tests are within the required limits.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
Stony Brook UniversityLead Sponsor
213 Previous Clinical Trials
39,464 Total Patients Enrolled
Stefan Madajewicz, MD, PhDStudy ChairStony Brook University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I haven't had any cancer except for skin cancer in the last 5 years.My colorectal cancer has returned or spread, and it can be measured.I can care for myself but may not be able to do active work.My liver function tests are within the required limits.My age is not a limiting factor for this trial.I have had a condition where my lymphocytes grow abnormally.I have a history of cancer.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any prerequisites to enrolling in this research study?
"Unfortunately, this particular clinical trial is no longer looking for new participants. Although the study was last updated over 10 years ago, there are still 1108 other trials that patients can take part in."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger